Search Results - "RIETSCHEL, Petra"

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial by Gogishvili, Miranda, Melkadze, Tamar, Makharadze, Tamta, Giorgadze, Davit, Dvorkin, Mikhail, Penkov, Konstantin, Laktionov, Konstantin, Nemsadze, Gia, Nechaeva, Marina, Rozhkova, Irina, Kalinka, Ewa, Gessner, Christian, Moreno-Jaime, Brizio, Passalacqua, Rodolfo, Li, Siyu, McGuire, Kristina, Kaul, Manika, Paccaly, Anne, Quek, Ruben G. W., Gao, Bo, Seebach, Frank, Weinreich, David M., Yancopoulos, George D., Lowy, Israel, Gullo, Giuseppe, Rietschel, Petra

“…First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously shown significant improvement in overall survival (OS) and…”
Get full text

Machine learning models for identifying predictors of clinical outcomes with first-line immune checkpoint inhibitor therapy in advanced non-small cell lung cancer by Li, Ying, Brendel, Matthew, Wu, Ning, Ge, Wenzhen, Zhang, Hao, Rietschel, Petra, Quek, Ruben G. W., Pouliot, Jean-Francois, Wang, Fei, Harnett, James

“…Immune checkpoint inhibitors (ICIs) are standard-of-care as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC) without actionable…”
Get full text

Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies by Kitano, Shigehisa, Shimizu, Toshio, Koyama, Takafumi, Ebata, Takahiro, Iwasa, Satoru, Kondo, Shunsuke, Shimomura, Akihiko, Fujiwara, Yutaka, Yamamoto, Noboru, Paccaly, Anne, Li, Siyu, Rietschel, Petra, Sims, Tasha

“…Purpose Part 1 of this two-part, open-label, Phase 1 study (NCT03233139) assessed the safety, tolerability, pharmacokinetics, immunogenicity, and clinical…”
Get full text

Variates of Survival in Metastatic Uveal Melanoma by RIETSCHEL, Petra, PANAGEAS, Katherine S, HANLON, Christine, PATEL, Ami, ABRAMSON, David H, CHAPMAN, Paul B

“…The course and outcome of metastatic uveal melanoma are not well described. We evaluated the survival of our patients with metastatic uveal melanoma, described…”
Get full text

Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50 by Freemantle, Nick, Xu, Yingxin, Wilson, Florence R., Guyot, Patricia, Chen, Chieh-I, Keeping, Sam, Konidaris, Gerasimos, Chan, Keith, Kuznik, Andreas, Atsou, Kokuvi, Glowienka, Emily, Pouliot, Jean-Francois, Gullo, Giuseppe, Rietschel, Petra

“…Background: For patients with advanced non-small-cell lung cancer (NSCLC) and high (⩾50%) programmed cell death-ligand 1 (PD-L1) expression, effective…”
Get full text

Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer by Feliciano, Josephine Louella, McLoone, Dylan, Xu, Yingxin, Quek, Ruben G W, Kuznik, Andreas, Pouliot, Jean-Francois, Gullo, Giuseppe, Rietschel, Petra, Guyot, Patricia, Konidaris, Gerasimos, Chan, Keith, Keeping, Sam, Wilson, Florence R, Freemantle, Nick

“…In randomized-controlled crossover design trials, overall survival (OS) treatment effect estimates are often confounded by the control group benefiting from…”
Get full text

600 Objective response impact on patient reported outcomes (PROs) in patients with aNSCLC with PD-L1 ≥50% receiving cemiplimab versus chemotherapy: EMPOWER-Lung 1 by Kilickap, Saadettin, Sezer, Ahmet, Gümü, Mahmut, Bondarenko, Igor, Özgüroğlu, Mustafa, Gogishvili, Miranda, He, Xuanyao, Gullo, Giuseppe, Rietschel, Petra, Quek, Ruben GW

“…BackgroundIn EMPOWER-Lung 1 (NCT03088540), a randomized 1:1 phase 3 open-label study comparing cemiplimab versus chemotherapy in patients with advanced NSCLC…”
Get full text

597 Preliminary results from LuCa-MERIT-1, a first-in-human Phase I trial evaluating the fixed antigen RNA vaccine BNT116 in patients with advanced non-small cell lung cancer by Deme, Dániel, Öven, Bala, Göker, Erdem, Lang, Istvan, Brück, Patrick, Wenger, Michael, Munshi, Neru, Schell, Thomas, Ünsal-Kaçmaz, Kezi, Markman, Janet, Rietschel, Petra, Yang, Huyuan, Tuereci, Oezlem, Sahin, Ugur, Atmaca, Akin, Forde, Patrick

“…BackgroundBNT116 is an intravenously administered RNA-lipoplex therapeutic cancer vaccine comprising six RNAs each encoding a tumor-associated antigen (TAA)…”
Get full text

Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and Lipodystrophy by Hadigan, Colleen, Meigs, James B., Corcoran, Colleen, Rietschel, Petra, Piecuch, Sarah, Basgoz, Nesli, Davis, Benjamin, Sax, Paul, Stanley, Takara, Wilson, Peter W. F., D'Agostino, Ralph B., Grinspoon, Steven

“…We evaluated metabolic and clinical features of 71 HIV-infected patients with lipodystrophy by comparing them with 213 healthy control subjects, matched for…”
Get full text

Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%–89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab by Ricciuti, Biagio, Elkrief, Arielle, Lin, Jessica, Zhang, Jianjun, Alessi, Joao V., Lamberti, Giuseppe, Gandhi, Malini, Di Federico, Alessandro, Pecci, Federica, Wang, Xinan, Makarem, Maisam, Hidalgo Filho, Cassio Murilo, Gorria, Teresa, Saini, Arushi, Pabon, Cindy, Lindsay, James, Pfaff, Kathleen L., Welsh, Emma L., Nishino, Mizuki, Sholl, Lynette M., Rodig, Scott, Kilickap, Saadettin, Rietschel, Petra, McIntyre, Debra AG, Pouliot, Jean-Francois, Altan, Mehmet, Gainor, Justin F., Heymach, John V., Schoenfeld, Adam J., Awad, Mark M.

“…Responses to first-line programmed cell death protein 1 inhibition vary among patients with metastatic NSCLC and a programmed death-ligand 1 (PD-L1) tumor…”
Get full text

Phase II Study of Extended-Dose Temozolomide in Patients With Melanoma by RIETSCHEL, Petra, WOLCHOK, Jedd D, KROWN, Susan, GERST, Scott, JUNGBLUTH, Achim A, BUSAM, Klaus, SMITH, Katherine, ORLOW, Irene, PANAGEAS, Katherine, CHAPMAN, Paul B

“…We conducted a phase II trial of extended-dose temozolomide (TMZ) in patients with melanoma to test the hypothesis that the approximately 30% response rate…”
Get full text

Prevalence of Hypogonadism among Men with Weight Loss Related to Human Immunodeficiency Virus Infection Who Were Receiving Highly Active Antiretroviral Therapy by Rietschel, Petra, Corcoran, Colleen, Stanley, Takara, Basgoz, Nesli, Klibanski, Anne, Grinspoon, Steven

“…Previous studies have indicated that there is a significant prevalence (50%) of hypogonadism among men with acquired immunodeficiency syndrome…”
Get full text

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial by Sezer, Ahmet, Kilickap, Saadettin, Gümüş, Mahmut, Bondarenko, Igor, Özgüroğlu, Mustafa, Gogishvili, Miranda, Turk, Haci M, Cicin, Irfan, Bentsion, Dmitry, Gladkov, Oleg, Clingan, Philip, Sriuranpong, Virote, Rizvi, Naiyer, Gao, Bo, Li, Siyu, Lee, Sue, McGuire, Kristina, Chen, Chieh-I, Makharadze, Tamta, Paydas, Semra, Nechaeva, Marina, Seebach, Frank, Weinreich, David M, Yancopoulos, George D, Gullo, Giuseppe, Lowy, Israel, Rietschel, Petra

“…We aimed to examine cemiplimab, a programmed cell death 1 inhibitor, in the first-line treatment of advanced non-small-cell lung cancer with programmed cell…”
Get full text

A phase I/II study of REGN5093, a MET x MET bispecific antibody, in patients with MET-altered advanced non-small cell lung cancer (NSCLC) by Rowlands, Tracey, Boyapati, Anita, Li, Siyu, Daly, Christopher, Seebach, Frank A., Lowy, Israel, Rietschel, Petra

“…Abstract only TPS9628 Background: Mesenchymal-epithelial transition (MET) factor is a transmembrane tyrosine kinase receptor activated by hepatocyte growth…”
Get full text

Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial by Makharadze, Tamta, Gogishvili, Miranda, Melkadze, Tamar, Baramidze, Ana, Giorgadze, Davit, Penkov, Konstantin, Laktionov, Konstantin, Nemsadze, Gia, Nechaeva, Marina, Rozhkova, Irina, Kalinka, Ewa, Li, Siyu, Li, Yuntong, Kaul, Manika, Quek, Ruben G W, Pouliot, Jean-Francois, Seebach, Frank, Lowy, Israel, Gullo, Giuseppe, Rietschel, Petra

“…EMPOWER-Lung 3 part 2 (NCT03409614), a double-blind, placebo-controlled phase 3 study, investigated cemiplimab (antiprogrammed cell death protein 1) plus…”
Get more information

A phase 1/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC by Drilon, Alexander E., Awad, Mark M., Gadgeel, Shirish M., Villaruz, Liza C, Sabari, Joshua K., Perez, Javier, Daly, Christopher, Patel, Shraddha, Li, Siyu, Seebach, Frank A., Lowy, Israel, Magnan, Heather D., Rietschel, Petra

“…TPS8593 Background: MET, also called hepatocyte growth factor receptor (HGFR), is a high-affinity transmembrane protein receptor for HGF. MET is overexpressed…”
Get full text

Quality of life with cemiplimab plus chemotherapy for first‐line treatment of advanced non–small cell lung cancer: Patient‐reported outcomes from phase 3 EMPOWER‐Lung 3 by Makharadze, Tamta, Quek, Ruben G. W., Melkadze, Tamar, Gogishvili, Miranda, Ivanescu, Cristina, Giorgadze, Davit, Dvorkin, Mikhail, Penkov, Konstantin, Laktionov, Konstantin, Nemsadze, Gia, Nechaeva, Marina, Rozhkova, Irina, Kalinka, Ewa, Gessner, Christian, Moreno‐Jaime, Brizio, Passalacqua, Rodolfo, Konidaris, Gerasimos, Rietschel, Petra, Gullo, Giuseppe

“…Background EMPOWER‐Lung 3, a randomized 2:1 phase 3 trial, showed clinically meaningful and statistically significant overall survival improvement with…”
Get full text

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial by Özgüroğlu, Mustafa, Kilickap, Saadettin, Sezer, Ahmet, Gümüş, Mahmut, Bondarenko, Igor, Gogishvili, Miranda, Nechaeva, Marina, Schenker, Michael, Cicin, Irfan, Ho, Gwo Fuang, Kulyaba, Yaroslav, Zyuhal, Kasimova, Scheusan, Roxana-Ioana, Garassino, Marina Chiara, He, Xuanyao, Kaul, Manika, Okoye, Emmanuel, Li, Yuntong, Li, Siyu, Pouliot, Jean-Francois, Seebach, Frank, Lowy, Israel, Gullo, Giuseppe, Rietschel, Petra

“…Cemiplimab provided significant survival benefit to patients with advanced non-small-cell lung cancer with PD-L1 tumour expression of at least 50% and no…”
Get full text

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial by Baramidze, Ana, Makharadze, Tamta, Gogishvili, Miranda, Melkadze, Tamar, Giorgadze, Davit, Penkov, Konstantin, Laktionov, Konstantin, Nemsadze, Gia, Nechaeva, Marina, Rozhkova, Irina, Kalinka, Ewa, AG McIntyre, Debra, Perez, Javier, Kaul, Manika, Quek, Ruben G.W., Seebach, Frank, Rietschel, Petra, Pouliot, Jean-Francois

“…•PD-L1 expression guides NSCLC treatment and regulatory approvals.•Study highlights efficacy of cemiplimab plus chemotherapy in PD-L1 ≥ 1 % population.•We…”
Get full text

Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo) by Vokes, Natalie I, Gandara, David R., Sezer, Ahmet, Kilickap, Saadettin, Gumus, Mahmut, Bondarenko, Igor, Özgüroğlu, Mustafa, Gogishvili, Miranda, Turk, Haci M., Cicin, Irfan, Bentsion, Dmitry, Liu, Jinrui, Giangreco, Nicholas, Wang, Fang, Li, Siyu, Lowy, Israel, Pouliot, Jean-Francois, Gullo, Giuseppe, Rietschel, Petra, Jankovic, Vladimir

“…9022 Background: While ctDNA has emerged as a promising tool for monitoring response on therapy, there is a paucity of data from prospective, randomised Phase…”
Get full text